Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer

International Journal of Cancer

Volumn 91, Issue 5, 2001, Pages 658-664

  Bea A Wisman, G ^a   Knol, Ageeth J ^a   Helder, Marco N ^a   Krans, Mindert ^a   De Vries, Elisabeth G E ^a   Hollema, Harry ^a   De Jong, Steven ^a   Van Der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cervical cancer; HTERT; HTR; Prognostic factor; Telomerase activity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; FLUOROURACIL; MESSENGER RNA; RNA; TELOMERASE; TELOMERASE RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FLUORESCENCE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

CERVIX UTERI; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYSTERECTOMY; LYMPHATIC METASTASIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TELOMERASE; TREATMENT OUTCOME; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 0035283897     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1099>3.0.CO;2-7     Document Type: Article

References (65)

1. Epidemiology of cervical cancer
2. Molecular biology of cervical cancer and its precursors
3. Stage I cervical adenocarcinoma: Prognostic evaluation of surgically treated patients
4. Long-term follow-up of stage I cervical adenocarcinoma treated by radical surgery
5. An analysis of cell type in patients with surgical stage IB carcinoma of the cervix: A Gynecologic Oncology Group study
6. Surgically-treated early cervical cancer: Prognostic factors and the significance of depth of tumor invasion
7. Ras oncogene expression and prognosis of invasive squamous cell carcinoma of the uterine cervix
8. Pretreatment serum squamous cell carcinoma antigen: A newly identified prognostic factor in early-stage cervical cancer
9. Favorable clinical outcome of cervical cancers infected with human papillomavirus type 58 and related types
10. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis
11. Detection and typing of human papillomavirus in cervical carcinomas in Russian women: A prognostic study
12. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: Possible implications for cervical cancer screening
13. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy
14. Telomerase activation by the E6 gene product of human papillomavirus type 16
15. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: Activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q
16. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas
17. Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents
18. Telomerase activity and survival of patients with node-positive breast cancer
19. Telomerase activity in ordinary meningiomas predicts poor outcome
20. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer
21. The RNA component of human telomerase
22. A mammalian telomerase-associated protein
23. Telomerase catalytic subunit homologs from fission yeast and human
24. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types
25. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization
26. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts
27. Reconstitution of human telomerase activity in vitro
28. Extension of life-span by introduction of telomerase into normal human cells
29. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase
30. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT
31. Reconstitution of wild-type or mutant telomerase activity in telomerase-negative immortal human cells
32. A telomerase component is defective in the human disease dyskeratosis congenita
33. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial lesions
34. Telomerase activation in cervical cancer
35. Telomerase activity as biomarker for (pre)-neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smears
36. Telomerase activity and expression of its RNA component in cervical lesions
37. Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions
38. Semiquantitative analysis of telomerase activity in cervical cancer and precancerous lesions
39. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization
40. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer
41. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: Strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavims DNA
42. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer
43. Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer
44. Concurrent chemo- and radiotherapy in patients with locally advanced carcinoma of the cervix
45. Cervical cancer
46. Tumors of the cervix, vagina and vulva
47. A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens
48. Expression profile of the putative catalytic subunit of the telomerase gene
49. Telomerase in (pre)neoplastic cervical disease
50. Alternative splicing of the telomerase catalytic subunit in human oocytes and embryos
51. Telomerase activity and prognosis in primary breast cancer
52. Telomerase activity and prognosis in breast cancer
53. Telomerase activity as a prognostic factor in stage I non-small cell lung cancer
54. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor
55. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay
56. Telomerase targeting in cancer treatment: New developments
57. Inhibition of human telomerase activity by peptide nucleic acids
58. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma ceils
59. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo
60. Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning
61. Antisense telomerase treatment: Induction of two distinct path-ways, apoptosis and differentiation
62. Inhibition of human telomerase by 2′-O-methyl-RNA
63. Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity
64. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
65. Multifactorial drug resistance in an adviamycin-resistant human small cell lung carcinoma cell line